Gain Therapeutics (NASDAQ:GANX) Releases Earnings Results, Beats Estimates By $0.07 EPS

Gain Therapeutics (NASDAQ:GANX) issued its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07, Zacks reports.

Gain Therapeutics Stock Performance

Shares of GANX stock traded down $0.06 during mid-day trading on Friday, reaching $2.01. The stock had a trading volume of 81,304 shares, compared to its average volume of 279,685. The firm has a market cap of $53.32 million, a PE ratio of -1.83 and a beta of 0.14. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a one year low of $0.89 and a one year high of $4.04. The firm’s 50 day simple moving average is $2.23 and its 200 day simple moving average is $2.05.

Analysts Set New Price Targets

A number of research analysts have weighed in on GANX shares. Scotiabank started coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, March 17th. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm reiterated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.20.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.